Versameb’s proprietary modifications of mRNA molecules translate into tailor-made protein expression and targeting by safely shuttling the therapy out of the cell. This optimization increases the therapeutic window and allows access to different disease targets and various cell types which were not amenable by common mRNA approaches.
Currently, we have proof of concept (PoC) in different tissues and for different protein classes including growth factors, hormones and cytokines. A significant increase in protein production and secretion as well as accelerated functional regeneration has been proven in various preclinical studies across multiple therapeutic applications. Our platform works as an innovation engine allowing us to rapidly generate new molecules for different targets and tissues.
The team is initially focusing on areas where localized delivery is the most appropriate way to address the clinical and biological drivers of the targeted disease. Our technology is equally applicable to therapies where systemic delivery would be optimal. The company is rapidly expanding into potential new targets and indications.